## atovaquone with proguanil

*antimalarial*

**Cautionary advisory labels:** B, D

### Notes

**Renal impairment (severe):** Caution. Consider alternative therapy.

**Pregnancy:** B2. Use not recommended, although previously commenced therapy may be continued. Seek advice from an infectious diseases specialist.

**Breastfeeding:** Use not recommended. Excretion into breast milk expected, but no safety data on drug in infants.

### Common dosage range

*Prophylaxis:* tablets should be taken once daily starting 1–2 days before entering an endemic area and continuing for 7 days after leaving the area.

*Treatment:* tablets should be taken once daily for three days.

**Adult dose**

*Prophylaxis:* one tablet (250/100 mg atovaquone/proguanil) daily.

*Treatment:* four tablets (250/100 mg atovaquone/proguanil) daily.

**Paediatric dose**

*Prophylaxis:*
11–20 kg: one tablet (62.5/25 mg atovaquone/proguanil) daily.

21–30 kg: two tablets (62.5/25 mg atovaquone/proguanil) daily.

31–40 kg: three tablets (62.5/25 mg atovaquone/proguanil) daily.

>40 kg: one tablet (250/100 mg atovaquone/proguanil) daily.

*Treatment:*

11–20 kg: one tablet (250/100 mg atovaquone/proguanil) daily.

21–30 kg: two tablets (250/100 mg atovaquone/proguanil) daily.

31–40 kg: three tablets (250/100 mg atovaquone/proguanil) daily.

>40 kg: four tablets (250/100 mg atovaquone/proguanil) daily.

## auranofin

*gold salt for rheumatoid arthritis*

**Cautionary advisory labels:** B

### Notes

- Mouth ulcers or stomatitis may be sign of systemic toxicity.
- Avoid in hypersensitivity to gold compounds or other heavy metals.
- Effect may not be evident for 3–4 months.

**Pregnancy:** B3. Use not recommended.

**Breastfeeding:** Use contraindicated. Potential to cause adverse effects (e.g. rash, nephritis, hepatitis, haematological abnormalities) in infants.

### Common dosage range

**Adult dose**

3–9 mg daily (increasing gradually) in one to three divided doses.

## aurothiomalate

*gold salt for rheumatoid arthritis*

### Notes

- Mouth ulcers or stomatitis may be sign of systemic toxicity.
- Monitor for 30 minutes after administration due to risk of anaphylaxis.

**Pregnancy:** B2. Use not recommended.

**Breastfeeding:** Use contraindicated. Potential to cause adverse effects (e.g. rash, nephritis, hepatitis, haematological abnormalities) in infants.

### Common dosage range

**Adult dose**

*Maintenance:* IM, 25–50 mg every 4–6 weeks.

**Paediatric dose**

*Juvenile rheumatoid arthritis:* 1 mg/kg (maximum 50 mg) every 2–4 weeks.

## azathioprine

*cytotoxic immunosuppressant*

**Cautionary advisory labels:** 8, 21, A*, B

### Notes

- Periodic blood monitoring is necessary.
- Advise patient to report any bleeding or excess bruising and to seek medical advice.

* Some products have specific indications or specialised formulations or coatings which give rise to instructions different from those applicable generally to the conventional dose form. In cases of doubt concerning specific products with specialised formulations or coatings, reference should be made to the recommendations contained in the manufacturer's information.